Silva Guilherme Almeida Rosa da, Andrade Mayra Christina Teixeira, Sugui Daniel de Alvarenga Salém, Nunes Rafael Fernandes, Pinto Jorge Francisco da Cunha, Eyer Silva Walter de Araujo, Ferry Fernando Raphael de Almeida, Azevedo Marcelo Costa Velho Mendes de, Motta Rogerio Neves
Universidade Federal do Estado do Rio de Janeiro, Rio de Janeiro, RJ, Brazil.
Arch Endocrinol Metab. 2015 Apr;59(2):116-22. doi: 10.1590/2359-3997000000023. Epub 2015 Apr 1.
This study aims to estimate the prevalence of thyroid diseases and anti-TPO status. We searched for an association among presence of immune reconstitution and use of stavudine, didanosine and protease inhibitors with thyroid diseases.
A cross-sectional study was performed to analyze the records of 117 HIV-infected patients who had their CD4+ cell count, viral load, anti-TPO, TSH and free T4 levels collected on the same day. Immune reconstitution was considered in those whose T CD4+ count was below 200 cells/mm3, but these values increased above 200 cells/mm3 after the use of antiretrovirals. The odds ratio obtained by a 2x2 contingency table and a chi-square test were used to measure the association between categorical variables.
The prevalence of thyroid disease was 34.18%; of these, 4.34% were positive for anti-TPO. There was an association of risk between stavudine use and subclinical hypothyroidism (OR = 4.19, 95% CI: 1.29 to 13.59, X2 = 6.37, p = 0.01). Immune reconstitution achieved protection associated with thyroid disease that was near statistical significance OR = 0.45, 95% CI: 0.19 to 1.04, X2 = 3.55, p = 0.059.
The prevalence of thyroid disease in the sample studied was higher than what had been found in the literature, with a low positive anti-TPO frequency. The historical use of stavudine has an association of risk for the presence of subclinical hypothyroidism, and immune reconstitution has trends towards protection for the presence of thyroid diseases.
本研究旨在评估甲状腺疾病的患病率及抗甲状腺过氧化物酶(anti-TPO)状态。我们探究免疫重建、司他夫定、去羟肌苷及蛋白酶抑制剂的使用与甲状腺疾病之间的关联。
开展一项横断面研究,分析117例HIV感染患者的记录,这些患者在同一天采集了CD4+细胞计数、病毒载量、anti-TPO、促甲状腺激素(TSH)及游离甲状腺素(free T4)水平。CD4+细胞计数低于200个细胞/mm³但在使用抗逆转录病毒药物后这些值升至200个细胞/mm³以上的患者被视为发生了免疫重建。通过2×2列联表及卡方检验获得的比值比用于衡量分类变量之间的关联。
甲状腺疾病的患病率为34.18%;其中,4.34%的患者anti-TPO呈阳性。使用司他夫定与亚临床甲状腺功能减退之间存在风险关联(比值比=4.19,95%置信区间:1.29至13.59,X²=6.37,p=0.01)。免疫重建对甲状腺疾病具有保护作用,接近统计学意义(比值比=0.45,95%置信区间:0.19至1.04,X²=3.55,p=0.059)。
在所研究的样本中,甲状腺疾病的患病率高于文献报道,anti-TPO阳性频率较低。司他夫定的既往使用与亚临床甲状腺功能减退的发生存在风险关联,且免疫重建对甲状腺疾病的发生有保护趋势。